Precision Medicine News and Research

RSS

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

ESMO Congress provides forum for presentation of new research on treatment of cancer

Cancer is a leading cause of mortality worldwide, accounting for more than one in ten deaths. By 2030, the global burden is expected to exceed 12 million.

9 Aug 2010

New MIC platform measures cell-signaling pathways in brain tumor samples at single-cell level

New technologies for the diagnosis of cancer are rapidly changing the clinical practice of oncology. As scientists learn more about the molecular basis of cancer, the development of new tools capable of multiple, inexpensive biomarker measurements on small samples of clinical tissue will become essential to the success of genetically informed and personalized cancer therapies.

4 Aug 2010

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

What As scientists understand more about a tumor's underlying biology, personalized medicine is emerging as the new patient management paradigm. This year, the American Association for Cancer Research will host its fourth Molecular Diagnostics in Cancer Therapeutic Development: Challenges and Horizons conference at the Sheraton Denver Downtown Hotel in Denver, Colo. This meeting regularly draws representatives from academia and industry to discuss the latest in diagnostic tools and emerging therapies.

4 Aug 2010

IRIS International closes AlliedPath acquisition

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has closed the acquisition of AlliedPath, Inc., a private, early stage high complexity, CLIA-certified laboratory focused on oncology and molecular diagnostics.

2 Aug 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

Champions Biotechnology fiscal 2010 operating revenues increase to $4.89 million

Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2010.

29 Jul 2010

New test to predict suitable treatment for chronic myeloid leukemia patients

Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML).

29 Jul 2010

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.

28 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

LabCorp second-quarter revenues increase 4.2% to $1,238.4 million

Laboratory Corporation of America® Holdings today announced results for the quarter ended June 30, 2010.

22 Jul 2010

CHLA receives $410,000 grant for 'first in childhood leukemia' multi-site study

J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.

21 Jul 2010

Jinfiniti Biosciences moves from clinical studies to developing biomarkers

A new biotech company has grown out of laboratory and clinical studies at the Medical College of Georgia with the goal of improving the diagnosis and treatment of diabetes and cancer.

20 Jul 2010

Univfy, Stanford scientists develop first validated prognostic test for predicting IVF live birth outcomes

Univfy, a pioneer in the development of personalized in vitro fertilization (IVF) prognostic tools, announced today the publication of new research findings in the journal Proceedings of the National Academy of Sciences (PNAS) by its founding scientific team and clinical collaborators from Stanford University.

20 Jul 2010

Microarrays acquired from Vanderbilt University

Microarrays, Inc. (MI), an innovator of array-based technologies for biological research, detection and diagnostics, today announced that the company's management team and a group of independent investors have purchased MI from Vanderbilt University. The new company structure will allow MI to more quickly and nimbly respond to client's rapidly expanding needs, especially within the diagnostic and health care arenas.

19 Jul 2010

FDA can promote personalized medicine by identying gaps in laboratory operations: ACLA

The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation's leading clinical laboratories, says that the factors supporting this approach include the growing role that such tests play in clinical decision making, especially in the area of new advanced diagnostics that derive from the mapping of the human genome and help fulfill the promise of personalized medicine.

17 Jul 2010

Agendia to provide testimony on federal regulation of laboratory developed tests

Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs).

16 Jul 2010

MD Anderson Cancer Center continues to rank first in cancer care

The University of Texas MD Anderson Cancer Center remains the leading hospital in the nation for cancer care for the fourth year straight, according to the annual "Best Hospitals" survey published by U.S. News & World Report.This is the seventh time in the last nine years that MD Anderson has ranked number one in the annual listing. Since the survey began in 1990, the institution has been ranked one of the top two cancer hospitals in the United States.

16 Jul 2010

Study reveals improved process to obtain, store RNA from lung tumor biopsies

Analyzing the genes expressed by cancer cells allows for a better understanding of that patient's specific disease and in turn, a more personalized approach to treatment. But obtaining the RNA from a tumor in the lungs in order to conduct the genetic analysis is a challenging prospect. Currently, lung cancer researchers are limited to using RNA extracted from early-stage tumors removed during surgery. The small quantities of tissue extracted during routine diagnostic biopsies have not been useful to researchers, due to their small size and the variety of ways they have been processed.

16 Jul 2010

Cryo-Cell second-quarter consolidated revenues decrease to $4.3 million

Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks, today announced results for the second quarter ended May 31, 2010. Consolidated revenues for the second quarter of fiscal 2010 were $4.3 million compared to $4.7 million for the second quarter of fiscal 2009.

15 Jul 2010

Precision Medicine News and Research

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

ESMO Congress provides forum for presentation of new research on treatment of cancer

New MIC platform measures cell-signaling pathways in brain tumor samples at single-cell level

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

IRIS International closes AlliedPath acquisition

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Champions Biotechnology fiscal 2010 operating revenues increase to $4.89 million

New test to predict suitable treatment for chronic myeloid leukemia patients

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Axela acquires Xceed Molecular

LabCorp second-quarter revenues increase 4.2% to $1,238.4 million

CHLA receives $410,000 grant for 'first in childhood leukemia' multi-site study

Jinfiniti Biosciences moves from clinical studies to developing biomarkers

Univfy, Stanford scientists develop first validated prognostic test for predicting IVF live birth outcomes

Microarrays acquired from Vanderbilt University

FDA can promote personalized medicine by identying gaps in laboratory operations: ACLA

Agendia to provide testimony on federal regulation of laboratory developed tests

MD Anderson Cancer Center continues to rank first in cancer care

Study reveals improved process to obtain, store RNA from lung tumor biopsies

Cryo-Cell second-quarter consolidated revenues decrease to $4.3 million

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News